A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression.

@article{Ribelles2008AC2,
  title={A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression.},
  author={Nuria Ribelles and Juan L{\'o}pez-Siles and {\`A}. Mediavilla S{\`a}nchez and Enrique Jos{\'e} San Emeterio Gonz{\'a}lez and M. J. S{\'a}nchez and Francisco J Carabantes and Pedro S{\'a}nchez-Rovira and Antonia M{\'a}rquez and Rosa Due{\~n}as and Isabel Sevilla and Emilio Alba},
  journal={Current drug metabolism},
  year={2008},
  volume={9 4},
  pages={336-43}
}
Capecitabine is a drug that requires the consecutive action of three enzymes: carboxylesterase 2 (CES 2), cytidine deaminase (CDD), and thymidine phosphorylase (TP) for transformation into 5-fluorouracil (5FU). The metabolism of 5FU requires the activity of thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) among other enzymes. The present study prospectively examined the possible relationship between the toxicity and efficacy of capecitabine and 14 different polymorphisms in… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

Optimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed?

Annals of oncology : official journal of the European Society for Medical Oncology • 2010
View 2 Excerpts
Highly Influenced

Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions-an Industry Perspective.

Drug metabolism and disposition: the biological fate of chemicals • 2016
View 1 Excerpt

Pharmacogenetic Predictors of Response.

Advances in experimental medicine and biology • 2016
View 1 Excerpt

Similar Papers

Loading similar papers…